Tenofomide Tablets 25Mg (1 Bottle = 30 Tablets)

Name: Tenofomide Tablets 25Mg (1 Bottle = 30 Tablets)
Brand: GETZ PHARMA PAKISTAN
Price: 3325

Brand : getz pharma pakistan

Rs. 3,325.00

Rs. 3,500.00

|

QUICK DELIVERY

Tenofomide Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Tenofovir Alafenamide

Used For

Hepatitis

How it works

Tenofovir alafenamide is a phosphonamidate prodrug of Tenofovir (2’-deoxyadenosine monophosphate analog). Tenofovir alafenamide as a lipophilic cell-permeant compound enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is then converted to Tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes. Intracellular Tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite Tenofovir diphosphate. Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase, which results in DNA chain-termination. Tenofovir has activity that is specific to hepatitis B virus and human immunodeficiency virus (HIV-1 and HIV-2). Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase ? and there is no evidence of toxicity to mitochondria in cell culture.

Tenofomide Tablets Usage And Safety

Dosage

Tenofovir Alafenamide

Side Effects

Very common : Headache. Common Dizziness, rash, pruritus, increased ALT, arthralgia, diarrhea, vomiting, nausea, abdominal pain, abdominal distension, flatulence, fatigue and cough .

Drug Interactions

Always consult your physician before using any medicine.

Indication

Tenofomide (Tenofovir alafenamide) is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years or above having body weight at least 35 kg).

When not to Use

Tenofovir alafenamide is contraindicated in patients with hypersensitivity to active substance or to any excipient of the product.

Tenofomide Tablets Precautions

Precaution

Discontinuation of anti-hepatitis B therapy, including Tenofovir alafenamide, may result in severe acute exacerbations of hepatitis B. Patients who discontinue Tenofovir alafenamide should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Tenofomide Tablets Warnings

Warning 1

Patients taking Tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents, including non-steroidal anti-inflammatory drugs are at increased risk of developing renal-related adverse reactions. It is recommended that serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose and urine protein be assessed before initiating Tenofovir alafenamide and during therapy in all patients as clinically appropriate. Discontinue Tenofovir alafenamide in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.

Warning 2

Patients must be advised that Tenofovir alafenamide does not prevent the risk of transmission of HBV to others through sexual contact or contamination with blood. Appropriate precautions must continue to be used.

Warning 3

Tenofovir alafenamide tablet contains lactose monohydrate. Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.

Download the Dvago App